iPS cell technology
Enhancing the Success Rate of Drug Development
Our innovative technology, 'AI × iPSC differentiation technology,'
may offer an enhanced opportunity to advance a pivotal role in advancing your new drug development efforts.
Human Gene Correlation Matrix
The Ricoh Group leverages the "Human Gene Correlation Matrix" database to identify the essential transcription factors for the differentiation of specific iPS-derived cells. This comprehensive database was created by introducing more than 700 transcription factors into ES cells and collecting the expression and image data for each transcription factor-introduced cell. Comparing it with the gene expression of the target cell, we determine the precise combination of transcription factors required for the differentiation of the target cell. Furthermore, we fine-tune the culture conditions for each target cell type, ensuring the production of high-quality iPS cell differentiated cells.
The Custom Development of iPS-derived Cells
Through the utilization of the "Human Gene Correlation Matrix," we can develop differentiation methods tailored to specific cell types. The Ricoh Group has already successfully established differentiation methods for a variety of cells, including neurons. the Ricoh Group offers unrestricted access to over 1,500 human patient-derived iPS cells that have been deposited in the California Institute for Regenerative Medicine (CIRM), without licensing.
AI-based high-content assay platform
Through the integration of the Ricoh Group's iPS cell differentiation technology and machine learning, we create phenotypic assays associated with neurodegenerative diseases, cancer, rare diseases, and infectious diseases. Utilizing patient-derived iPS cells for disease model construction enables the recapitulation of specific diseases. Additionally, with the High Content image assay, we can comprehensively assess the effects, mechanisms, and actions of drugs related to these specific diseases by analyzing multiple parameters simultaneously. These phenotypic screenings can play a crucial role in enhancing the success rate of new drug development.
iPSC-derived Cell Therapy
The Ricoh group creates tailored iPSC differentiation methods for cell therapy and regenerative medicine applications, ensuring efficient and consistent cell production. Ricoh has implemented a robust production system featuring a culture processing center (CPC) with the goal of achieving off-the-shelf production of cell therapy products.
